Welcome to our dedicated page for Unity Btech SEC filings (Ticker: UNBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Unity Biotechnology, Inc. (UNBX) provides access to key regulatory documents that explain the company’s transition from a listed issuer to a dissolved corporation. Unity Biotechnology, Inc. used Forms 8-K and Form 15, among others, to disclose material events such as exchange delisting, stockholder approval of dissolution, lease terminations, and the termination of its reporting obligations.
Unity Biotechnology, Inc.’s 8-K filings describe how its common stock, par value $0.0001 per share, was suspended from trading on The Nasdaq Stock Market LLC, subsequently delisted after Nasdaq filed a Form 25 with the SEC, and then traded on the OTC Pink Limited Market under the symbol UNBX. These reports also detail the special meeting of stockholders at which the liquidation and dissolution of the company and the Plan of Complete Liquidation and Dissolution were approved, including the voting results for the dissolution and adjournment proposals.
Another 8-K records the filing of a Certificate of Dissolution with the Secretary of State of Delaware, effective September 26, 2025, and explains the consequences for stockholders, including closure of the stock transfer books and the rights of stockholders under Delaware law for a dissolved corporation. The same and related filings outline operational wind-down steps, such as a Lease Termination Agreement and Amendment for office and laboratory space and a Sublease Termination Agreement with a subtenant.
Unity Biotechnology, Inc.’s Form 15 is central for understanding its reporting status. In this document, the company certifies and gives notice of the termination of registration of its common stock under Section 12(g) of the Exchange Act and the suspension of its duty to file reports under Sections 13 and 15(d), citing Rule 12g-4(a)(1) and Rule 15d-6. On this page, users can follow these filings to see how UNBX moved from active reporting to deregistration and dissolution. AI-powered tools on the platform can help summarize the main points of lengthy filings, highlight important items such as dissolution steps and changes in trading status, and make complex legal language more accessible.
Unity Biotechnology, Inc. received an amended Schedule 13G/A (Amendment No. 4) from ARCH-affiliated entities and managers stating they beneficially own 0 shares and represent 0% of the common stock (CUSIP 91381U200). The date of the event requiring the filing is 09/30/2025.
Each reporting person—ARCH Venture Fund VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; related ARCH Venture Partners entities; and individuals Keith Crandell, Robert Nelsen, and Clinton Bybee—reports 0 sole/shared voting power and 0 sole/shared dispositive power.
Unity Biotechnology, Inc. submitted a Certificate of Dissolution for the company that is effective September 26, 2025, and executed a Lease Termination Agreement and Amendment with Bayside Area Development, LLC dated September 24, 2025. The filing also references an interactive XBRL cover page and is signed by Craig Jalbert, President. These actions indicate formal steps to dissolve the corporate entity and to end at least one lease arrangement in late September 2025.
The document contains core corporate-closeout actions but no financial statements, forward guidance, or details about creditor claims, asset transfers, or shareholder distributions. There is insufficient transactional or financial detail in this filing to assess impacts on creditors, investors, or ongoing contractual obligations beyond the cited lease termination and the effective dissolution date.
Unity Biotechnology, Inc. held a special stockholder meeting where investors approved a proposal authorizing a potential corporate dissolution and an adjournment proposal related to that meeting. The voting power present represented 600,944,604 votes, or 97.36% of the outstanding voting power entitled to vote.
Stockholders approved the Dissolution Proposal by 450,228,768 votes for and 150,685,568 against, with 30,268 abstentions. A separate Adjournment Proposal was also approved. The Board now has discretion to determine the timing of filing a Certificate of Dissolution, to proceed with, amend, or abandon the dissolution under Delaware law.
The company warns that trading in its securities is highly speculative and risky, and that trading prices may bear little or no relationship to any value ultimately realized by security holders.